Steve Bernitz has taken the role of general partner at Cambridge-based Extera Partners, a life sciences-focused firm specializing in partnerships, acquisitions and new product commercialization.
Bernitz previously served as chief business officer at small molecule drug maker Concert Pharmaceuticals Inc., where he led the company’s $1 billion partnership with GlaxoSmithKline. According to the Extera website , he has also worked as CEO of clinical stage cell therapy firm Histogenics Corp., senior vice president of business and commercial development at Coley Pharmaceutical Group Inc., a vaccine adjuvant technology developer that was bought by Pfizer Inc., and CEO of Organogenesis Inc., a maker of skin treatment products.
Before moving to life sciences, Bernitz held positions in private equity and as a consultant. He earned an MBA from Northwestern University and a bachelor’s degree from Tufts University.
Extera Partners maintains its U.S. office in Cambridge and its European office in Hall, Germany. The firm brings together a network of advisors from such industries as pharmaceuticals, imaging, medical devices and diagnostics.